American leadership on innovation policy is essential to global health progress
By Ernest Kawka | May 4, 2021
Over the last year, the world has witnessed the importance of strong innovation policies as intellectual property protection and market access policies facilitated the research, development and...
Read More
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
By Megan Van Etten | April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...
Read More
Intellectual property is the key to vaccine development, manufacturing and technology sharing
By Megan Van Etten | March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...
Read More
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
By Tom Wilbur | February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...
Read More
Preserving U.S. innovation worldwide is more important than ever
By Megan Van Etten | January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
New video: See how strong IP protections lead to stronger treatments for patients
By Tom Wilbur | November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | October 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
By Tom Wilbur | September 30, 2020
The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
